Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

An up to Twelve Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Pediatric Subjects

This study has been completed.
Sponsor:
Information provided by:
Graceway Pharmaceuticals, LLC
ClinicalTrials.gov Identifier:
NCT00116662
First received: June 30, 2005
Last updated: February 16, 2007
Last verified: November 2006

June 30, 2005
February 16, 2007
March 2005
Not Provided
Clearance of treated common wart(s)
Same as current
Complete list of historical versions of study NCT00116662 on ClinicalTrials.gov Archive Site
  • Partial clearance of treated common wart(s)
  • Wart recurrence
Same as current
Not Provided
Not Provided
 
An up to Twelve Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Pediatric Subjects
A Single-Blind, Dose-Escalating Study to Assess Efficacy and Safety of Resiquimod Gel Applied 3 Times Per Week for up to 12 Weeks for the Treatment of Common Warts in Pediatric Subjects

The primary purpose of this study is to evaluate the effectiveness in pediatric subjects of three different strengths of resiquimod gel applied to common wart(s) three times a week for up to twelve weeks.

A second purpose is to evaluate the safety of the drug.

Not Provided
Interventional
Phase 2
Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Single Blind
Primary Purpose: Treatment
Warts
Drug: Resiquimod
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
84
Not Provided
Not Provided

Inclusion Criteria:

  • Diagnosis of common wart(s)
  • Ages between 3 to 11

Exclusion Criteria:

  • Other types of wart(s), ie. plantar
  • Currently participating in another clinical study
  • Chronic viral hepatitis B or C
Both
3 Years to 11 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00116662
1534-RESI
Not Provided
Not Provided
Graceway Pharmaceuticals, LLC
Not Provided
Not Provided
Graceway Pharmaceuticals, LLC
November 2006

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP